(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
Figurine of a woman and a goose offers peek at prehistoric beliefs- Reporter's notebook: Inside the IDF’s ‘Hamas Village,’ and how Israel is rewriting urban warfare
- Which camera do you believe is great for first-time clients? !
- From Representative to Business visionary: Private issue Victories
- As reefs vanish, assisted coral fertilization offers hope in the Dominican Republic
- Thousands of genomes reveal the wild wolf genes in most dogs’ DNA
- It Looks Like a Tiny, Fluffy Dragon, But It's Really a Bird. Meet the Great Eared Nightjar
- Surveys of Music Collections by Film Stars
- 6 Top of the line Lodgings All over The Planet, Which One Do You Concur With
